RIA (Research and Innovation Action)

PIONEER is funded by the Innovative Medicines Initiative (IMI) 2, set up under Big Data for Better Outcomes (BD4BO), part of the EU’s Horizon 2020 Programme, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Grant Agreement No 777492.

01/05/2018 – 30/04/2023 (5 years)

University of Aberdeen

VIEW PARTNERS >

EFPIA companies

Astellas Pharma Europe BV, Leiden, Netherlands

Bayer Aktiengesellschaft, Leverkusen, Germany

Covance Laboratories LTD, Harrogate, United Kingdom

IMS Information Solutions Medical Research Limited

Janssen Pharmaceutica Nv, Beerse, Belgium

Nv SAS Institute SA, Tervuren, Belgium

Orion Oyj, Espoo, Finland

Sanofi-Aventis Recherche & Développement, Chilly Mazarin, France

Universities, research organisations, public bodies and non-profit groups

Association Eisbm, Vourles, France

Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands

European Alliance for Personalised Medicine Asbl, Brussels, Belgium

European Organisation for Research and Treatment of Cancer Aisbl, Brussels, Belgium

Fraunhofer Gesellschaft Zur Foerderung der Angewandten Forschung E.V., Munich, Germany

Goeteborgs Universitet, Gothenburg, Sweden

Imperial College of Science, Technology and Medicine, London, United Kingdom

King’s College London, London, United Kingdom

Lunds Universitet, Lund, Sweden

Stichting Katholieke Universiteit, Nijmegen, Netherlands

Tampereen Korkeakoulusaatio Sr

Technische Universitaet Dresden, Dresden, Germany

 

Universities, research organisations, public bodies and non-profit groups

The University Court of the University of Aberdeen, Aberdeen, United Kingdom

Universita Vita-Salute San Raffaele, Milan, Italy

Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany

Weizmann Institute of Science LTD, Rehovot, Israel

 

Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)

Ihe, Institutet For Halso- Och Sjukvardsekonomi Aktiebolag, Lund, Sweden

International Consortium for Health Outcomes Measurement LTD, London, United Kingdom

Pinsent Masons LLP, London, United Kingdom

Stichting European Urological Foundation, Arnhem, Netherlands

The Ecancer Global Foundation, Bristol, United Kingdom

The Hyve BV, Utrecht, Netherlands

Ttopstart BV, Bilthoven, Netherlands

 

Patient organisations

European Cancer Patient Coalition (ECPC), Brussels, Belgium

Why it matters

Prostate cancer (PCa) is the second leading cause of cancer in men, accounting for 9% of all cancer deaths among men in Europe. The socio-economic burden associated with it is predicted to dramatically increase in the coming years due to aging. Currently, it is hard to predict which patients will respond best to different treatments, and which patients can be managed safely without undergoing treatment.

PIONEER is one of the BD4BO disease-specific projects and serves as the European Network of Excellence for Big Data in Prostate Cancer. The project is using big data to address key knowledge gaps related to screening, diagnosis and treatment of prostate cancer by standardising and integrating already existing big data in clinical trials and electronic health records from diverse populations of prostate cancer patients across different stages of the disease into a single, innovative data platform. PIONEER is working for meaningful improvement in clinical practice, improved health outcomes and increased health-system efficiency by providing evidence-based data, so patients can benefit from the best possible care.

“It is vital to have a prostate cancer awareness campaign at European and national level. Treat the patient, not the cancer.”

Ken Mastris, ECPC Board Member

What ECPC does

ECPC is contributing to the overall project by providing a voice to prostate cancer patients through offering expert patient input and advice during the entire life cycle of the project. The participation of ECPC ensures that the patients engage in their disease management, thus leading to better treatment adherence and improved Quality of Life (QoL). This includes and is not limited to reviewing informed consent forms, surveys, study protocols and guidelines, setting up patient focus groups, drafting patient information leaflets and brochures, and the successful communication and dissemination of the project’s deliverables. ECPC is also working to ensure that the visual identity of PIONEER is aligned with the branding of the DO-IT communication and support action for all BD4BO projects supported by the IMI.

EU flag logo

This project is funded by the European Union